Eli Lilly (LLY) has secured a second FDA approval for its oral SERD Inluriyo in under a year, this time in combination with its CDK4/6 inhibitor Verzenio.
The regimen is now approved for adults with estrogen receptor-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy.
The approval builds on Inluriyo’s existing monotherapy indication, which the FDA granted in September 2025 for the same patient population.
Data from the phase 3 Ember-3 trial showed the Inluriyo-Verzenio combination helped patients achieve a median progression-free survival of 11.1 months, compared with 5.5 months for Inluriyo alone.
That improvement translates into a 47% reduction in the risk of disease progression or death, giving Lilly a compelling clinical argument for physicians choosing between treatment options.
Jacob Van Naarden, executive vice president and president of Lilly Oncology, said Inluriyo is already the leading treatment option for the relevant patient population, now reaching over half of all patients starting an oral SERD.
Van Naarden projected that most patients will choose the combination over oral SERD monotherapy, given the longer progression-free survival data supporting the regimen.
“Today’s full approval extends what Inluriyo in combination with Verzenio can do for patients, with a regimen that has confirmed benefit, is aligned to the clinically proven treatment paradigm of changing therapy at clinical progression, and doesn’t introduce burdensome monitoring requirements for patients or physicians,” Van Naarden said.
The adjuvant setting remains the largest market opportunity for oral SERDs, and Van Naarden argued that tolerability will ultimately determine which therapy comes out on top.
“That’s really important in the adjuvant setting where patients are going to be on these medicines for like five to 10 years,” he said, adding: “You only get the benefit of the medicine if you take it.”
Permanent discontinuation of Inluriyo alone due to adverse reactions in the combination arm occurred in just 1% of patients during clinical trials.
Permanent discontinuation of Verzenio alone in the combination arm occurred in 3.4% of patients, suggesting the regimen carries a manageable tolerability profile.
Lilly is already studying Inluriyo in the phase 3 EMBER-4 trial in the adjuvant setting, targeting patients with ER-positive, HER2-negative early-stage breast cancer at increased risk of recurrence following standard endocrine therapy.
EMBER-4 is described as the largest adjuvant oral SERD clinical trial in the world, with more than 8,000 patients enrolled globally.
Competition in the oral SERD space is intensifying, with Roche’s giredestrant currently under FDA priority review for ER-positive, HER2-negative breast cancer, with a regulatory decision expected by 30 November.
Roche’s giredestrant is also under a separate FDA review in combination with a kinase inhibitor for ESR1-mutated patients who have undergone a prior endocrine-based regimen, with a decision expected by 18 December.
Lilly’s latest approval positions Inluriyo as a cornerstone asset across multiple lines of breast cancer treatment as the company works to consolidate its lead in a rapidly evolving therapeutic category.